WEIDANZ LAB

The Weidanz lab sits on the cutting edge of cancer immunotherapy research integrating the latest tools in antibody development and spatial biology to make ground breaking  discoveries. Antibody development and design has been a major part of the Weidanz lab and we continue to produce antibodies intended to inhibit immune checkpoint pathways. The lab is involved in the forefront of spatial proteomics and single-cell RNA-seq through the Akoya biosciences and 10x platforms. Dr. Weidanz partners with the leaders in clinical immunological and computational biology and industry in the Dallas-Fort Worth area to push the limits of biomedical research in new and innovative ways.

Dr. Jon A Weidanz

Jon Weidanz, MPH, Ph.D. is the Associate Vice President for Research, Professor with tenure, College of Nursing and Health Innovation and College of Engineering, and a member of the Multi-Professional Center for Health Informatics at the University of Texas at Arlington (UTA). He founded the North Texas Genome Center at UTA in 2018 and served as its director until 2022. Dr. Weidanz has broad experience and interest in biotechnology with particular knowledge and expertise in immunology and immunotherapy research and product development. He has more than 60 peer-reviewed articles, book chapters and published conference proceedings and has been an invited speaker at more than 50 conferences, universities and companies.

While at Texas Tech University Health Sciences Center, he was named as a Distinguished Professor and recognized for his teaching accomplishments, receiving the prestigious President’s Excellence in Teaching Award and the Chancellor’s Council Distinguished Teaching Award.